Nowadays, patients with advanced NSCLC harboring sensitizing mutations can achieve survival rates at least double by treated with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.